SEC Company Response from GT Biopharma, Inc. (GTBP) (CIK 0000109657) (GTBP) — Mar 21, 2018
GT Biopharma, Inc. (GTBP) (CIK 0000109657)
Date: March 21, 2018 · CIK: 0000109657 · Accession: 0001654954-18-002886
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-223348
Letter
Blueprint
March 21, 2018
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549-3628
Attention:
Chris Edwards, Special Counsel
Erin Jaskot, Special Counsel
Re:
GT Biopharma, Inc.
Registration Statement on Form S-3 (File No. 333-223348)
Filed March 1, 2018
Acceleration Request
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, GT Biopharma, Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) accelerate the effectiveness of the above-referenced Registration Statement on Form S-3 to 2:00 p.m., Eastern Time, on March 22, 2018, or as soon thereafter as practicable. The Registrant hereby authorizes Jenifer R. Smith of DLA Piper LLP (US), counsel to the Registrant, to orally modify or withdraw this request for acceleration.
We request that we be notified of the effectiveness of the Registration Statement by telephone to Jenifer R. Smith of DLA Piper LLP (US) at (512) 457-7037. We also respectfully request that a copy of the Commission’s order declaring the Registration Statement effective be sent to Jenifer R. Smith via facsimile at (512) 721-2212. Thank you for your assistance.
Very
truly yours,
GT
BIOPHARMA, INC.
Show Raw Text
CORRESP
1
filename1.htm
Blueprint
March
21, 2018
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549-3628
Attention:
Chris Edwards, Special Counsel
Erin Jaskot, Special Counsel
Re:
GT Biopharma, Inc.
Registration Statement on Form S-3 (File
No. 333-223348)
Filed March 1, 2018
Acceleration Request
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended,
GT Biopharma, Inc. (the “Registrant”)
hereby respectfully requests that the Securities and Exchange
Commission (the “Commission”)
accelerate the effectiveness of the above-referenced Registration
Statement on Form S-3 to 2:00 p.m., Eastern Time, on March 22,
2018, or as soon thereafter as practicable. The Registrant hereby
authorizes Jenifer R. Smith of DLA Piper LLP (US), counsel to the
Registrant, to orally modify or withdraw this request for
acceleration.
We request that we be notified of the effectiveness of the
Registration Statement by telephone to Jenifer R. Smith of DLA
Piper LLP (US) at (512) 457-7037. We also respectfully request that
a copy of the Commission’s order declaring the Registration
Statement effective be sent to Jenifer R. Smith via facsimile at
(512) 721-2212. Thank you for your assistance.
Very
truly yours,
GT
BIOPHARMA, INC.
By: /s/ Steven
Weldon
Steven
Weldon
Chief
Financial Officer
cc:
Shawn Cross, Chief Executive Officer
Jenifer R. Smith, DLA Piper LLP
(US)